ES2643268T3 - Métodos para identificar anticuerpos neutralizantes contra VIH - Google Patents

Métodos para identificar anticuerpos neutralizantes contra VIH Download PDF

Info

Publication number
ES2643268T3
ES2643268T3 ES13758886.9T ES13758886T ES2643268T3 ES 2643268 T3 ES2643268 T3 ES 2643268T3 ES 13758886 T ES13758886 T ES 13758886T ES 2643268 T3 ES2643268 T3 ES 2643268T3
Authority
ES
Spain
Prior art keywords
binding
fusion protein
cell
hiv
binding site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13758886.9T
Other languages
English (en)
Spanish (es)
Inventor
Julián Miguel BLANCO ARBUÉS
Jorge Carrillo Molina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IrsiCaixa Institut de Recerca de la Sida
Esteve Pharmaceuticals SA
Original Assignee
IrsiCaixa Institut de Recerca de la Sida
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IrsiCaixa Institut de Recerca de la Sida, Laboratorios del Dr Esteve SA filed Critical IrsiCaixa Institut de Recerca de la Sida
Application granted granted Critical
Publication of ES2643268T3 publication Critical patent/ES2643268T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
ES13758886.9T 2012-09-06 2013-09-06 Métodos para identificar anticuerpos neutralizantes contra VIH Active ES2643268T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382342.9A EP2706356A1 (en) 2012-09-06 2012-09-06 Methods for identifying HIV neutralizing antibodies
EP12382342 2012-09-06
PCT/EP2013/068446 WO2014037490A1 (en) 2012-09-06 2013-09-06 Methods for identifying hiv neutralizing antibodies

Publications (1)

Publication Number Publication Date
ES2643268T3 true ES2643268T3 (es) 2017-11-21

Family

ID=46829683

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13758886.9T Active ES2643268T3 (es) 2012-09-06 2013-09-06 Métodos para identificar anticuerpos neutralizantes contra VIH

Country Status (16)

Country Link
US (1) US9952218B2 (https=)
EP (2) EP2706356A1 (https=)
JP (1) JP6282655B2 (https=)
KR (1) KR20150081255A (https=)
CN (1) CN104755933B (https=)
AU (1) AU2013311626A1 (https=)
BR (1) BR112015004970A2 (https=)
CA (1) CA2884165A1 (https=)
ES (1) ES2643268T3 (https=)
IL (1) IL237613A0 (https=)
IN (1) IN2015DN02730A (https=)
MX (1) MX2015003047A (https=)
PT (1) PT2893349T (https=)
RU (1) RU2015112297A (https=)
WO (1) WO2014037490A1 (https=)
ZA (1) ZA201502210B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106166313B (zh) * 2016-07-01 2018-09-07 浙江大学 一种艾滋病孕妇血液净化器
CN106075626B (zh) * 2016-07-01 2018-06-26 浙江大学 一种艾滋病血液净化治疗仪

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US7115262B1 (en) * 1999-03-16 2006-10-03 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein for prevention and treatment of HIV infection
WO2003040311A2 (en) * 2001-10-25 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
EP1523492A4 (en) * 2002-07-23 2006-05-10 Univ Duke IGG FC / HIV GP120 / C3D FUSION PROTEIN
US8197819B2 (en) * 2004-06-08 2012-06-12 Novartis Vaccines And Diagnostics, Inc. Env polypeptide complexes and methods of use
ATE471947T1 (de) * 2005-02-03 2010-07-15 Novartis Vaccines & Diagnostic Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür
CN101551392A (zh) * 2008-01-22 2009-10-07 厦门大学 一种检测人乳头瘤病毒中和抗体的方法
CN101846679A (zh) * 2009-03-25 2010-09-29 邢安辉 筛选含有外源融合基因HIV/env/IFNα-2b的重组痘苗病毒的方法
EP3957651A1 (en) * 2010-05-21 2022-02-23 The United States of America, as Represented By the Secretary, Department of Health and Human Services High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins

Also Published As

Publication number Publication date
PT2893349T (pt) 2018-04-12
WO2014037490A1 (en) 2014-03-13
IN2015DN02730A (https=) 2015-09-04
MX2015003047A (es) 2015-07-14
AU2013311626A1 (en) 2015-04-30
KR20150081255A (ko) 2015-07-13
CN104755933B (zh) 2017-06-09
CA2884165A1 (en) 2014-03-13
EP2706356A1 (en) 2014-03-12
EP2893349B1 (en) 2017-08-16
CN104755933A (zh) 2015-07-01
EP2893349A1 (en) 2015-07-15
JP6282655B2 (ja) 2018-02-21
ZA201502210B (en) 2016-11-30
JP2015530575A (ja) 2015-10-15
US9952218B2 (en) 2018-04-24
RU2015112297A (ru) 2016-10-27
US20150233924A1 (en) 2015-08-20
IL237613A0 (en) 2015-04-30
HK1211694A1 (en) 2016-05-27
BR112015004970A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
KR102443389B1 (ko) Sarsr-cov에 대한 항체의 검출
US20250129171A1 (en) Car t-cell therapy directed to lhr for the treatment of solid tumors
Ou et al. Role of protein disulfide isomerase and other thiol-reactive proteins in HIV-1 envelope protein-mediated fusion
Wang et al. Enhanced SARS-CoV-2 neutralization by secretory IgA in vitro
Morozov et al. Single mutations in the transmembrane envelope protein abrogate the immunosuppressive property of HIV-1
Lapointe et al. People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses
Hong et al. Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120
US10722571B2 (en) Rabies virus G protein epitope, and rabies virus neutralising binding molecule that binds specifically thereto
EP4299586A2 (en) Methods and compositions for the detection and diagnosis of renal disease and periodontal disease
Dimitrov et al. A mechanism of resistance to HIV-1 entry: inefficient interactions of CXCR4 with CD4 and gp120 in macrophages
Ringe et al. Association of enhanced HIV-1 neutralization by a single Y681H substitution in gp41 with increased gp120-CD4 interaction and macrophage infectivity
US20250296985A1 (en) Potently neutralizing novel human monoclonal antibodies against sars-cov-2 (covid-19)
Armani-Tourret et al. Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis
Bristow et al. α1Proteinase inhibitor regulates CD4+ lymphocyte levels and is rate limiting in HIV-1 disease
ES2643268T3 (es) Métodos para identificar anticuerpos neutralizantes contra VIH
Toyoda et al. Impaired ability of Nef to counteract SERINC5 is associated with reduced plasma viremia in HIV-infected individuals
US6251582B1 (en) Alternative G-coupled receptors associated with retroviral entry into cells, methods of identifying the same, and diagnostic and therapeutic uses thereof
ES2327340T3 (es) Procedimiento y dispositivo para detectar el virus de la inmunodeficiencia felina.
Wang et al. Neutralization efficiency is greatly enhanced by bivalent binding of an antibody to epitopes in the V4 region and the membrane-proximal external region within one trimer of human immunodeficiency virus type 1 glycoproteins
Carrillo et al. Gp120/CD4 blocking antibodies are frequently elicited in ART-naive chronically HIV-1 infected individuals
HK1211694B (en) Methods for identifying hiv neutralizing antibodies
JP5614409B2 (ja) トキソカラ症を検出するための組換え抗原
Deshpande et al. Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies
Oladimeji Impact of HIV-2 ROD9 Vpx Mutations on SAMHD1 Degradation and Vpx Nuclear Trafficking
Sukmak Development of in-house ELISA for Bovine Leukemia Virus (BLV) detection for Thai dairy industry